Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting.

Next Previous
Trial Profile

A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Coronary disorders; Coronary stent thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EASY

Most Recent Events

  • 10 Nov 2008 Results of a cost-minimisation analysis of the EASY trial presented at the 81st Scientific Sessions of the American Heart Association (AHA), 2008.
  • 13 Sep 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top